Tower Research Capital (TRC)’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-12,849
| Closed | -$51.4K | – | 5413 |
|
|
2025
Q2 | $51.4K | Buy |
12,849
+242
| +2% | +$599 | ﹤0.01% | 2950 |
|
|
2025
Q1 | $11.5K | Buy |
12,607
+8,884
| +239% | +$12.3K | ﹤0.01% | 3534 |
|
|
2024
Q4 | $10.3K | Buy |
3,723
+1,921
| +107% | +$7.31K | ﹤0.01% | 3813 |
|
|
2024
Q3 | $9.42K | Sell |
1,802
-4,717
| -72% | -$24.5K | ﹤0.01% | 3868 |
|
|
2024
Q2 | $29.1K | Buy |
6,519
+6,121
| +1,538% | +$29.7K | ﹤0.01% | 3506 |
|
|
2024
Q1 | $3.05K | Sell |
398
-3,494
| -90% | -$19.2K | ﹤0.01% | 4938 |
|
|
2023
Q4 | $16.6K | Sell |
3,892
-4,440
| -53% | -$15.8K | ﹤0.01% | 3775 |
|
|
2023
Q3 | $35K | Buy |
8,332
+4,777
| +134% | +$24.3K | ﹤0.01% | 2881 |
|
|
2023
Q2 | $19.8K | Sell |
3,555
-10,538
| -75% | -$62.3K | ﹤0.01% | 3397 |
|
|
2023
Q1 | $81K | Buy |
14,093
+10,495
| +292% | +$27.7K | ﹤0.01% | 2060 |
|
|
2022
Q4 | $4K | Buy |
+3,598
| New | +$6.29K | ﹤0.01% | 5018 |
|
|
2022
Q2 | – | Sell |
-2,430
| Closed | -$10K | – | 6282 |
|
|
2022
Q1 | $10K | Buy |
2,430
+1,028
| +73% | +$6.05K | ﹤0.01% | 4315 |
|
|
2021
Q4 | $10K | Buy |
1,402
+597
| +74% | +$5.16K | ﹤0.01% | 4571 |
|
|
2021
Q3 | $9K | Sell |
805
-374
| -32% | -$5.83K | ﹤0.01% | 4443 |
|
|
2021
Q2 | $20K | Buy |
1,179
+20
| +2% | +$348 | ﹤0.01% | 3886 |
|
|
2021
Q1 | $23K | Sell |
1,159
-241
| -17% | -$5.32K | ﹤0.01% | 3777 |
|
|
2020
Q4 | $29K | Buy |
1,400
+141
| +11% | +$3.36K | ﹤0.01% | 3594 |
|
|
2020
Q3 | $33K | Buy |
+1,259
| New | +$31.3K | ﹤0.01% | 3694 |
|
Tower Research Capital (TRC)'s INZY Position: Q3 2025 in Review
Tower Research Capital (TRC) sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 12,849 shares — an estimated $51.4K sold.
Tower Research Capital (TRC) first reported a position in INZY in Q3 2020 and held it in 18 quarters. The position peaked at $81K in Q1 2023. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.
- Tower Research Capital (TRC) reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
- Tower Research Capital (TRC) sold 12,849 Inozyme Pharma shares in Q3 2025, an estimated $51.4K.
- Tower Research Capital (TRC) first reported a position in Inozyme Pharma in Q3 2020 and held it in 18 quarters.
- Tower Research Capital (TRC)'s Inozyme Pharma position peaked at $81K in Q1 2023.
- 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2025, filed 14 Nov 2025.